C11orf63 Inhibitors
C11orf63 inhibitors encompass compounds that target specific intracellular signaling pathways that could be responsible for the regulation of C11orf63. PI3K inhibitors, such as LY294002 and Wortmannin, inhibit the PI3K/AKT pathway, crucial for numerous cellular processes including growth, proliferation, and survival. By inhibiting PI3K, these compounds could reduce AKT activity, which may be necessary for the activation or function of C11orf63. Similarly, the mTOR pathway, targeted by compounds like Rapamycin, is essential for protein synthesis and cell growth; inhibition of this pathway could lead to a decrease in the proteins that are regulated by mTOR, potentially affecting C11orf63 if it is part of this regulatory network.
In addition to pathways involved in cell growth and survival, the MAPK/ERK pathway is another critical signaling cascade that can be modulated to affect protein function. MEK inhibitors such as U0126 and PD98059 act by blocking the activation of ERK1/2, which may be necessary for the phosphorylation and subsequent activity of various proteins, including potentially C11orf63.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor that can suppress AKT phosphorylation and subsequent downstream signaling. If C11orf63 were to be regulated by the PI3K/AKT pathway, LY294002 inhibition of PI3K would lead to decreased AKT activity, potentially reducing C11orf63 activity if it requires PI3K/AKT signaling for its function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor that operates similarly to LY294002. Wortmannin’s inhibition of PI3K would reduce AKT-mediated signaling processes, which could indirectly inhibit C11orf63 if it is dependent on PI3K/AKT signaling for its activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can disrupt the mTORC1 signaling cascade. Since mTORC1 is involved in protein synthesis and cell growth, inhibition by Rapamycin could lead to reduced activity of C11orf63 if it relies on mTORC1 signaling for its function or expression. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
MEK inhibitor that prevents ERK phosphorylation, part of the MAPK/ERK pathway. If C11orf63 is activated by ERK signaling, U0126 would lead to decreased ERK activity and potentially inhibit C11orf63 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor that would inhibit p38 MAPK signaling. If C11orf63 function is facilitated by p38 MAPK activity, then SB203580 would lower its functional activity through this inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that can reduce JNK signaling. If the JNK pathway is responsible for activating C11orf63, inhibition by SP600125 would result in decreased activity of C11orf63. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Src family kinase inhibitor that can downregulate multiple signaling pathways including those that may activate C11orf63. If C11orf63 is downstream of Src kinase signaling, Dasatinib inhibition could lead to reduced activity of C11orf63. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
RAF inhibitor that can block the RAF/MEK/ERK signaling pathway. If C11orf63 is dependent on this pathway for its activity, Sorafenib could indirectly inhibit C11orf63 by reducing pathway signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor that prevents the activation of the MAPK/ERK pathway. If C11orf63 requires MAPK/ERK signaling for its activity, PD98059 could result in decreased activity of C11orf63. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Src kinase inhibitor that can suppress Src family kinase-mediated signaling. If C11orf63 is activated by Src kinases, PP2 could lead to decreased activity of C11orf63. | ||||||